potassium chloride/glucose fresenius 1,5 mg/50 mg/ml šķīdums infūzijām
fresenius kabi deutschland gmbh, germany - kalii chloridum, glikozes - Šķīdums infūzijām - 1,5 mg/50 mg/ml
potassium chloride/glucose fresenius 3 mg/50 mg/ml šķīdums infūzijām
fresenius kabi deutschland gmbh, germany - kalii chloridum, glikozes - Šķīdums infūzijām - 3 mg/50 mg/ml
glucose b.braun 5% šķīdums infūzijām
b.braun melsungen ag, germany - glikoze - Šķīdums infūzijām - 5%
glucose b.braun 10% šķīdums infūzijām
b.braun melsungen ag, germany - glikoze - Šķīdums infūzijām - 10%
zeposia
bristol-myers squibb pharma eeig - ozanimod hidrohlorīds - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imūnsupresanti - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
onureg
bristol-myers squibb pharma eeig - azacitidine - leikēmija, mieloīds, akūts - antineoplastiski līdzekļi - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
nulojix
bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imūnsupresanti - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.
thalidomide bms (previously thalidomide celgene)
bristol-myers squibb pharma eeig - talidomīds - multiple mieloma - imūnsupresanti - thalidomide bms in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy. thalidomide bms is prescribed and dispensed according to the thalidomide celgene pregnancy prevention programme (see section 4.
septabene ar citronu un plūškoku 3 mg/1 mg sūkājamās tabletes
krka, d.d., novo mesto, slovenia - benzydamini hydrochloridum, cetylpyridinii chloridum - sūkājamā tablete - 3 mg/1 mg
ursofalk 250 mg/5 ml suspensija iekšķīgai lietošanai
dr. falk pharma gmbh, germany - ursodezoksiholskābe - suspensija iekšķīgai lietošanai - 250 mg/5 ml